Breaking News
Investing Pro 0
Cyber Monday Extended SALE: Up to 60% OFF InvestingPro+ CLAIM OFFER
Close

Precigen Inc (PGEN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Precigen's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.890 +0.070    +3.85%
02/12 - Closed. Currency in USD ( Disclaimer )
After Hours
1.830
-0.060
-3.175%
17:33:49 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 515,821
  • Bid/Ask: 1.820 / 1.920
  • Day's Range: 1.760 - 1.900
Precigen 1.890 +0.070 +3.85%

Precigen Inc Company Profile

 
Get an in-depth profile of Precigen Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology
SectorHealthcare
Employees

484

Equity Type

ORD

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Contact Information

Top Executives

Name Age Since Title
Jeffrey B. Kindler 65 2011 Independent Director
Dean Jonathan Mitchell 65 2009 Independent Director
Steven R. Frank 61 2008 Independent Director
James S. Turley 66 2014 Independent Director
Cesar L. Alvarez 73 2008 Independent Director
Helen Sabzevari 59 2017 President, CEO & Director
Randal J. Kirk 68 2008 Executive Chairman
Vinita D. Gupta 53 2017 Independent Director
Robert B. Shapiro 82 2011 Lead Independent Director
Fred Hassan 75 2016 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PGEN Comments

Write your thoughts about Precigen Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jay Jay
Jay Jay Mar 18, 2021 6:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
20% bump today with FDA orphan drug designation.
Jeff Bailey
JeffB Mar 01, 2021 5:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
PGEN $8.20 -2.84% @ Close (Earnings)
Jeff Bailey
JeffB Feb 23, 2021 10:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
PGEN $8.27 +0.61% @ Close! Sideways since exit, but holding tough in a weaker NASDQ market.
Jeff Bailey
JeffB Feb 14, 2021 3:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
PGEN $8.33 @ Friday Close!
Jeff Bailey
JeffB Feb 11, 2021 12:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
PGEN $8.30 @ 12:52 PM ET ... Stopped on 1/2 bull. Flat of PGEN
Jeff Bailey
JeffB Feb 09, 2021 2:31PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
PGEN $8.80 +1.15% ... raising bull stop to $8.30 from $7.30. @ 02:30 PM ET.
Jeff Bailey
JeffB Feb 05, 2021 6:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
PGEN $8.10 @ Friday close!
Jeff Bailey
JeffB Feb 05, 2021 6:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This week's trade at $7.50 is a triple bottom sell signal, which negates the previously noted bull vertical count. My stop loss is firm $7.35. The trade at $7.50 could be a "bear trap" should we get a reversal back up to $10.00, which would get the shares back on a buy signal. Bullish support trend @ $6.50.
Jeff Bailey
JeffB Jan 27, 2021 2:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
PGEN .... brought to my attention by Guns and Glory in VX chat 1/26/2021.  Bull vertical count to $19.50 is upper end of retracement.  Recent Secondary Offering at $7.50.  Secondary probably shorted by underwriters as a hedge, but they are covered.  However, sell side firms may be short, undhedged, belief that secondary is diluted.  #11 on NASDAQ short interest and good environment for a short squeeze. https://invst.ly/tluey
Carlos Andres
Carlos Andres Oct 15, 2020 10:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Very bullish from 2nd June, when a fund bought a lot of shares.
Lynn Szeto
Lynn Szeto Jun 04, 2020 10:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy or sell?
Orlando Vargas
Orlando Vargas Jun 04, 2020 10:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy. Its up today 20%
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email